MARKET

TNDM

TNDM

Tandem Diabetes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

122.43
-0.67
-0.54%
After Hours: 123.00 +0.57 +0.47% 19:10 09/17 EDT
OPEN
122.42
PREV CLOSE
123.10
HIGH
123.63
LOW
120.24
VOLUME
8.75M
TURNOVER
--
52 WEEK HIGH
130.73
52 WEEK LOW
76.19
MARKET CAP
7.72B
P/E (TTM)
1219.42
1D
5D
1M
3M
1Y
5Y
BlackRock Advantage SMID Cap V.I. Fund Buys Owens-Corning Inc, UGI Corp, PTC Inc, Sells Pool ...
GuruFocus News · 20h ago
Tandem Diabetes Care Inc (TNDM) EVP & CHIEF COMMERCIAL OFFICER Brian B Hansen Sold $3. ...
GuruFocus News · 2d ago
Insider Sell: Tandem Diabetes Care
MT Newswires · 2d ago
Here's Why Tandem Diabetes Care, Inc. (TNDM) is a Strong Momentum Stock
Zacks.com · 2d ago
Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.
Zacks · 3d ago
BlackRock Advantage SMID Cap Fund, Inc. Buys Owens-Corning Inc, UGI Corp, PTC Inc, Sells Pool ...
GuruFocus News · 4d ago
Insider Of Tandem Diabetes Care Trades $733.89 Thousand In Company Stock
James Leal, Insider at Tandem Diabetes Care (NASDAQ:TNDM), made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September ...
Benzinga · 09/09 23:15
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TNDM. Analyze the recent business situations of Tandem Diabetes through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TNDM stock price target is 132.75 with a high estimate of 165.00 and a low estimate of 90.00.
EPS
Institutional Holdings
Institutions: 424
Institutional Holdings: 68.03M
% Owned: 107.94%
Shares Outstanding: 63.03M
TypeInstitutionsShares
Increased
108
4.48M
New
54
2.86M
Decreased
94
3.77M
Sold Out
41
1.18M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Chairman/Executive Director
Kim Blickenstaff
President/Chief Executive Officer/Director
John Sheridan
Chief Financial Officer/Executive Vice President/Treasurer
Leigh Vosseller
Executive Vice President/Chief Administrative Officer
Susan Morrison
Executive Vice President/Chief Compliance Officer/Secretary
David Berger
Executive Vice President
Elizabeth Gasser
Executive Vice President
Brian Hansen
Vice President
Jordan Pinsker
Lead Director/Independent Director
Dick Allen
Independent Director
Peyton Howell
Independent Director
Kathleen McGroddy-Goetz
Independent Director
Rebecca Robertson
Independent Director
Douglas Roeder
Independent Director
Rajwant Sodhi
Independent Director
Christopher Twomey
No Data
About TNDM
Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. The Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.

Webull offers kinds of Tandem Diabetes Care Inc stock information, including NASDAQ:TNDM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNDM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TNDM stock methods without spending real money on the virtual paper trading platform.